JBN Biotech ApS: Financial statements 2022
CVR: 40685693
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
JBN Biotech ApS (CVR 40685693) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -16,158 and a net result of DKK 31,880,629 compared with DKK 4,337,323 the year before. Equity in the 2022 report amounted to DKK 35,611,899. The solvency ratio was 72.4%.
- Gross Profit
- DKK -16,158
- Profit/Loss
- DKK 31,880,629
- Equity
- DKK 35,611,899
- Total Assets
- DKK 49,211,323
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -16 t. | 31.9 mio. | 35.6 mio. | 0 |
| 2021 | - | -16 t. | 4.3 mio. | 3.7 mio. | 0 |
| 2020 | - | -27 t. | -646 t. | -606 t. | 0 |
Official annual report
Keep an eye on JBN Biotech ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout JBN Biotech ApS
JBN Biotech ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2019. The company is registered under the industry Anden finansiel formidling i.a.n.. The management consists of Jens Bredal Nielsen. The company is owned by Jens Bredal Nielsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -22,188 and a net result of DKK -222,807 compared with DKK -263,330 the year before. Equity in the 2025 report amounted to DKK 34,941,304.